484
Participants
Start Date
January 31, 2016
Primary Completion Date
December 31, 2017
Study Completion Date
December 31, 2017
RVT-101 35 mg
once daily, oral, 35-mg tablets
RVT-101 70 mg
once daily, oral, 35-mg tablets
Placebo
once daily, oral, matching tablets
US109, New York
IT300, Genoa
US120, Willow Grove
US123, Washington D.C.
IT301, Milan
US101, Charlottesville
IT306, Brescia
IT302, Brescia
US100, Chapel Hill
US136, Atlanta
FR952, Toulouse
US111, Jacksonville
US122, Orlando
US137, Palm Beach Gardens
US104, Boca Raton
US116, Boca Raton
US126, Tampa
US105, Lexington
US106, Columbus
US110, Cleveland
FR953, Saint-Herblain
US118, Indianapolis
FR955, Vandœuvre-lès-Nancy
US102, Rochester
FR957, Lille
US112, Chicago
FR950, Strasbourg
FR951, Villeurbanne
FR954, Bron
IT304, Tricase
FR959, Paris
FR956, Paris
FR960, Paris
US124, Dallas
US141, Englewood
US138, Phoenix
US108, Phoenix
US139, Sun City
US125, Tucson
US133, Rancho Mirage
US119, Irvine
US134, Oxnard
US140, Sacramento
US131, Portland
US135, Newton
US130, Quincy
CA200, Toronto
CA201, Sherbrooke
IT305, Venice
NE402, Amsterdam
NE401, 's-Hertogenbosch
NE400, Rotterdam
SP600, Barcelona
SP605, Barcelona
SP602, Burgos
UK801, Cambridge
UK808, Epping
UK804, Southampton
UK807, Bristol
UK806, Dundee
UK805, Isleworth
UK800, London
UK809, London
UK802, Manchester
UK803, Newcastle upon Tyne
Lead Sponsor
Axovant Sciences Ltd.
INDUSTRY